Rehovot (Israel), January 14, 2010

Foamix Ltd., a leading developer of topical foams for dermatological and gynecological use, announced today that the United States Patent Office has granted the company a key patent, protecting foam formulations comprising saccharides.

Foamix has been granted United States Patent No. 7,645,803, entitled "SACCHARIDE FOAMABLE COMPOSITIONS". It covers unique foamable compositions, which comprise saccharides, such as monosaccharides, disaccharides, oligosaccharides and honey. Foamable compositions, as well as methods of treatment and of drug delivery using them are claimed in the patent.

"This patent grant adds depth to Foamix’s patent portfolio and enhances the position of our multiple foam technologies and delivery systems," stated Dr. Dov Tamarkin, CEO of Foamix.

"The granted claims re-enforce our broad intellectual property portfolio and evidence our pioneering role in the development of medicated foams. Moreover, it is another milestone achieved through Foamix’s continuing investment in an extensive research and development program on foam technology," explained Dr. Tamarkin.

About Foamix’s Saccharide Foam

Foamix develops multiple proprietary foam platforms for effective and safe delivery of topical drugs. Our technological platforms include emollient foam formulations, which comprise oil in water or water in oil emulsion, Ointment-Foam, which is occlusive, Waterless Hydrophilic Foam, based on hydrophilic solvents, Oil Foam, Hydro-Ethanolic Foam, Potent-Solvent Foam, which consist of unique pharmaceutical solvents, Suspension Foam and Saccharide Foam.

The Foamix foams are easy to apply and spread, they disappear into the skin quickly, and offer the cosmetic elegance of fine skin care products. They can be used as carriers for a variety of drugs, including steroids, hormones, antibacterials, antifungals, antivirals, immunomodulators, local anesthetics, vitamins, anti-allergics, hair growth agents, and insect killing/repelling agents.

The Foamix’s saccharide foam is a unique topical formulation. In certain cases the saccharide concentration is high enough to make the composition hygroscopic, thereby enhancing its microbicidal effects. Various saccharides and honey are also known to have wound healing properties; and thus, the Foamix foam compositions can be used in the treatment of wounds and burns, either alone or in combination with additional wound healing agents.

About Foamix:

Headquartered in Rehovot, Israel, Foamix Ltd. is a leading developer of topical and mucosal foams for dermatological and gynecological applications. Foamix’s state-of-the-art foams provide controlled delivery of a variety of active ingredients. Foamix is currently collaborating with pharmaceutical and cosmetic companies on a range of projects in the development of proprietary dermatological and gynecologic foam products. Additionally, the Company has an in-house pipeline of dermatological and gynecological formulations in foam presentation. Foamix’s psoriasis foam product licensed to Dr. Reddy's Laboratories and marketed by Promius Pharma under the trade mark Scytera™ was launched in the United States in early 2009.

To-date, Foamix has nineteen issued patents worldwide covering its foam and OilGel technology platforms and over 150 pending applications, of which more than 60 are filed in the United States.

For additional information please visit www.foamix.co.il